Matthew W. Foehr
President & CEO at OmniAb Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 2 boards, counting each seat separately. Longest: Viking Therapeutics Inc., 3 years.
Viking Therapeutics Inc.
Director
OmniAb Inc.
Director · President and CEO
Chief executive roles
OmniAb Inc.
· President & CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 7, 2026 | OmniAb Inc. | Option exercise | +36,459 | — | — |
| Apr 7, 2026 | OmniAb Inc. | Open-market sale | −19,244 | $1.49 | $28,674 |
| Feb 18, 2026 | OmniAb Inc. | Option exercise | +58,333 | — | — |
| Feb 18, 2026 | OmniAb Inc. | Open-market sale | −30,843 | $1.71 | $52,742 |
| Feb 17, 2026 | OmniAb Inc. | Open-market sale | −20,754 | $1.70 | $35,282 |
| Feb 16, 2026 | OmniAb Inc. | Option exercise | +36,458 | — | — |
| Jan 2, 2026 | Viking Therapeutics Inc. | Option exercise | +16,000 | $3.33 | $53,280 |
| Jan 2, 2026 | Viking Therapeutics Inc. | Open-market sale | −16,000 | $35.11 | $561,760 |
| Jan 2, 2026 | Viking Therapeutics Inc. | Grant or award | +3,150 | — | — |
| Dec 8, 2025 | OmniAb Inc. | Open-market sale | −13,666 | $1.96 | $26,785 |
| Dec 7, 2025 | OmniAb Inc. | Option exercise | +26,554 | — | — |
| Aug 26, 2025 | OmniAb Inc. | Grant or award | +540,540 | $1.85 | $999,999 |
| Apr 11, 2025 | Viking Therapeutics Inc. | Option exercise | +20,786 | $8.00 | $166,288 |
| Apr 7, 2025 | OmniAb Inc. | Option exercise | +36,458 | — | — |
| Apr 7, 2025 | OmniAb Inc. | Open-market sale | −19,382 | $2.00 | $38,764 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.